Outspoken doctor’s pancreas study prompted FDA’s new diabetes-drug probe

Carly Helfand

Inconclusive data, confounding variables, as-yet-unreplicated results–they're all reasons critics have dismissed a link between incretin mimetics, a class of diabetes drugs including blockbusters Januvia and Byetta, and pancreatic cancer.

FiercePharma News

Share This Post

Related Articles

Leave a Reply

© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS